Veranova A CDMO that manages complexity with confidence

Veranova A CDMO that manages complexity with confidence

X

Find Clinical Drug Pipeline Developments & Deals by Acousia Therapeutics

Acousia Therapeutics

About, Contact Details

EVENTS

Webinars & Exhibitions

Webinars & Exhibitions

PRESENTATION(s)

No Presentations

VIDEO(s)

No Video

DIGITAL CONTENT

4 News

4 News

DEVELOPMENTS

3 Drug(s) in Development

3 Drug(s) in Development

Developments

Filters

×

FILTER:

filter

Company

filter

Sponsor

filter

Country

filter

Therapeutic Area

filter

Study Phase

Active Filter(s):

Filters

Reset Filter

All Developments

Companies By Therapeutic Area

Development Status

Acousia Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Hearing Loss Company Acousia Therapeutics to Present Data for Lead Candidates ACOU085 & ACOU082 at ARO 2023 Mid Winter Meeting February 11-15

Details:

ACOU085 is a proprietary small molecule, etiology-agnostic otoprotective drug candidate, expected to finish a first-in-man clinical Phase 1b study by late 2022 using standard transtympanic administration of a slow-release gel formulation.

Lead Product(s): ACOU085

Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: ACOU085

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 24, 2022

ASK
US

Upload
your Pipeline Activity

Acousia Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Acousia Therapeutics to Present Its First-in-class Hearing Loss Treatment Program With ACOU085 at the 2nd Inner Ear Therapeutics Summit in Boston

Details:

ACOU085 is a proprietary, first-in-class, small-molecule otoprotective drug candidate, which is currently being tested in a Phase 1b clinical trial involving age-related hearing loss (ARHL) patients.

Lead Product(s): ACOU085

Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: ACOU085

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 11, 2022

ASK
US

Upload
your Pipeline Activity

Acousia Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Hearing Loss Company Acousia Therapeutics: First Patient With Age-related Hearing Loss Treated With ACOU085

Details:

ACOU085 is a proprietary small-molecule, otoprotective drug candidate that modulates a well-defined molecular target preferentially expressed in the sensory cells of the inner ear, the so-called outer hair cells (OHC).

Lead Product(s): ACOU085

Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: ACOU085

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 05, 2022

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY